The peripheral vascular market encompasses devices that are used to treat peripheral arterial disease (PAD) associated conditions that affect these regions such as aneurysms and emboli.
An obvious factor that is driving this market is the aging population, a demographic that is associated with higher rates of vascular conditions. In addition, modifications to existing technologies, such as lower profile devices are allowing physicians to more effectively treat more difficult vasculature including below the knee regions. If you are interested in knowing more about this market click this link to receive a free copy of the executive summary.
One of the standard methods to open up vascular constrictions is PTA balloon angioplasty. This method typically does not remove the plaque, with the notable exception of scoring balloons. Because the plaque is still present following balloon angioplasty and the process causes physical trauma, the chance of restenosis is high, affecting over two thirds of patients. However, developments such as cryoplasty and drug-eluting balloons have been successful in decreasing the rates of restenosis. An alternative method to open up vascular constriction is through the physical clearing arterial plaques such as in the case of an endarterectomy. An atherectomy is another method to debulk the vasculature. This procedure, in contrast to an endarterectomy, is a minimally invasive mechanical means to remove plaque from an artery. In addition, atherectomy devices are useful for clearing vasculature that is too narrow for conventional stenting procedures such as regions below the knee. Clearing vascular blockages in the lower limbs is critical because failure to resolve these vascular limitations can result in critical limb ischemia, ulceration, limb pain or eventual amputation if left untreated. Approximately 150,000 amputations are performed in the U.S. every year with more than 90% of these due to circulatory complications.
Transcatheter embolization is a useful tool for treating vessel malformations such as aneurysms, fistulae and hemorrhaging. If left untreated, some of these arterio-venous malformations can ultimately lead to strokes. In addition, transcatheter embolization is and effective therapy for obstructing blood flow to tumors or organs; thus starving the target tissues. This is an effective therapeutic treatment for managing tumors or fibroids that are inaccessible via conventional surgical methods. The transcatheter embolization market also encompasses specialized particles, such as drug-coated and radiolabeled beads which are used for the targeted delivery of drugs and for radiation therapy respectively. These applications can be very expensive, and can cost over $14,000 per application in the case of radioembolization particles.
To treat aneurysms, embolic material is delivered to the lesion. The embolics pack the aneurysm sac and in the case of coils, form a thrombus to stop the bleeding and prevent further blood flow into the sac. It is estimated that one in twenty people have an aneurysm. Moreover, the chances of getting an aneurysm increase rapidly for those over the age of 30. Thus, the potential market for embolotherapy is large. Because of the versatility of embolic devices to treat various conditions, growth in their market is expected to be strong. For example, the market for particle embolics is expected to grow at a compound annual growth rate (CAGR) of over 20% during the 2011 to 2018 period.
The information in this post is taken from our latest U.S. Peripheral Vascular Device Market report.